stockrowBridgeBio Pharma, Inc.
BBIO Healthcare Biotechnology
BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024.
- Revenue
- +192.6%
- EPS
- +55.8%
- Free cash flow
- +60.5%
- Total debt
- +4.21%
Quarter to September 2026, against a year earlier
Follow BBIO
Alert me
BridgeBio Pharma, Inc. (BBIO) Gross margin
BridgeBio Pharma, Inc.'s gross margin over the twelve months to 30 September 2026 was 94.3%, down 1.5 percentage points from fiscal 2025 (95.8%). Over the past ten years it has ranged from 0.00% (fiscal 2017) to 100.0% (fiscal 2020); the current reading is higher than 75% of that period. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 95.8% | (2.43) |
| FY2024 | 98.3% | 24.54 |
| FY2023 | 73.7% | (21.87) |
| FY2022 | 95.6% | 0.05 |
| FY2021 | 95.5% | (4.47) |
| FY2020 | 100.0% | 6.16 |
| FY2019 | 93.8% | 93.84 |
| FY2017 | 0.00% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 94.2% | 0.38 |
| Jun 2026 | 93.8% | (1.06) |
| Mar 2026 | 94.9% | 0.15 |
| Dec 2025 | 94.7% | 0.18 |
| 23 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| SMMT Summit Therapeutics PLC compare | 100.0% |
| KYMR Kymera Therapeutics, Inc. compare | 100.0% |
| EXEL Exelixis, Inc. compare | 96.3% |
| BBIO BridgeBio Pharma, Inc. | 94.3% |
| ASND Ascendis Pharma A/S compare | 91.3% |
| JAZZ Jazz Pharmaceuticals PLC compare | 89.1% |
| HALO Halozyme Therapeutics, Inc. compare | 82.3% |
| BMRN BioMarin Pharmaceutical Inc. compare | 76.0% |
| TECH Bio-Techne Corp compare | 65.8% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on BBIO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement